Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

BACKGROUND: Pemafibrate, a selective PPARα modulator, has the beneficial effects on serum triglycerides (TGs) and very low density lipoprotein (VLDL), especially in patients with diabetes mellitus or metabolic syndrome. However, its effect on the low density lipoprotein cholesterol (LDL-C) levels is...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiya, Ichiro, Yamamoto, Akira, Sunakawa, Suguru, Wakugami, Tamio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897372/
https://www.ncbi.nlm.nih.gov/pubmed/33610176
http://dx.doi.org/10.1186/s12944-021-01434-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897372/
https://www.ncbi.nlm.nih.gov/pubmed/33610176
http://dx.doi.org/10.1186/s12944-021-01434-8

Ejemplares similares